NCT06918808招募中2 期
A Phase 2a Study of Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product (DB-3Q) in Patients With Perianal Fistulizing Crohn's Disease
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 36
- 试验地点
- 5
- 主要终点
- Combined Remission
研究概览
简要总结
This is a double-blind, randomized, placebo-controlled, sequential cohort, ascending dose clinical trial to evaluate the safety and determine the efficacy of ascending doses of DB-3Q for the treatment of Perianal Fistulizing Crohn's Disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent from participant
- •Men and women 18-75 years of age with a diagnosis of Crohn's Disease for at least six months duration prior to Day 1
- •One or two perianal fistula(s) with 1 or two external openings, that are actively draining
- •Failed at least one medical therapy within the last year including, but not limited to, antibiotics, immunomodulators (6-MP, methotrexate, azathioprine), monoclonal antibodies (adalimumab, certolizumab, golimumab, guselkumab, infliximab, risankizumab, ustekinumab, vedolizumab), or small molecule inhibitors (tofacitinib, upadacitinib)
- •Previous failed surgical intervention, including seton placement at least two weeks prior to screening, or are not candidates for surgical intervention or are not willing to undergo surgical intervention for the management of their fistula
- •Medical therapy for CD stable for at least 2 months prior to Day 1 (Changes in dosing or dosing intervals related to serum drug levels are not permitted)
- •Antibiotics for the treatment of CD (e.g., ciprofloxacin, metronidazole, or rifaximin) must have been stable for at least 2 weeks prior to Day 1
- •Oral corticosteroids ≤ 20 mg/day prednisone or its equivalent and must have been stable for at least 4 weeks prior to Day 1
- •Approval of a screening pelvic MRI by review of a central radiologist. The definition of an acceptable screening pelvic MRI is provided in the study imaging manual.
- •Fulfillment of radiologic inclusion by a central radiologist. Radiologic inclusion on MRI is presence of 1 or 2 qualifying perianal fistula(s). Radiologic inclusion assesses anatomic criteria of a perianal fistula and study-defined imaging endpoint criteria. a. Anatomically, a qualifying perianal fistula on MRI fulfills the following from central radiologist assessment: i. has a communication with the internal sphincter of the anal canal ii. is classified as a Parks intersphincteric, transsphincteric, or suprasphincteric perianal fistula. b. For study imaging endpoints, a central radiologist confirms that a fistula has a minimum score of 7 (range 0 to 25) on MAGNIFI-CD and a fistula fibrosis -to-fluid ratio of less than 80%.25, 37 Within components of MAGNIFI-CD, the fistula has a length of 2.5 cm or greater and has a composition of either 'predominantly fluid/pus' or 'predominantly granulation tissue'. c. Within components of fistula fibrosis-to-fluid ratio, the ratio of hypointense scarring or fibrosis on MRI T2 weighted sequences to hyperintense fluid on MRI T2 weighted sequences is below 80%.25 The fistula is categorized into one of following ranges of fibrosis-to- fluid ratio: i) 0%, ii) 1-19%, iii) 20-39%, iv) 40-59%, or v) 60-79%
排除标准
- •Lack of informed consent
- •Pregnant woman, woman of childbearing potential without a documented negative urine or serum pregnancy test, or woman who is breast feeding
- •A participant who is unwilling to use medically acceptable contraception methods during participation in study
- •Active perianal abscess or infection at screening or Day 1
- •Clinically significant medical conditions within six months before Day 1 that would, in the opinion of the Investigator, compromise the safety of the participant
- •Confirmed HIV, Hepatitis B, or Hepatitis C infections
- •History of cancer including melanoma (with the exception of localized non-melanoma skin cancers) within one year of screening
- •History of colorectal cancer within 2 years of screening
- •History of coagulation disorders and/or are currently on anti- coagulant therapy
- •Presence of a recto/ano-vaginal fistula
- •Presence of an ileal anal pouch and/or history of proctectomy
- •Presence of severe proctitis (SES CD >6)
- •Any condition which, in the opinion of the Investigator, would make it unsafe or unsuitable for participant to undergo MRI evaluations (i.e., presence of implantable or external MRI unsafe device that cannot be removed, body weight exceeding limitations, claustrophobia, etc.)
- •The following out of range laboratory results at screening
- •WBC > 13 x 109 /L
- •Hemoglobin < 8 g/dL
- •Platelet count < 100,000/mL
- •AST/ALT > 3 times the upper limit of normal
- •Creatinine > 2 μmol/L
- •PT/INR: 2 times the upper limit of normal
- •Hemoglobin A1c > 6.5 mg/dL
- •Use of investigational therapy or treatment within 30 days prior to Day 1
- •Does not meet the radiologic anatomic inclusion criteria: i) has a primary communication with the rectum and not the anal canal; ii) is classified as a Parks extrasphincteric fistula
- •Does not meet the minimum thresholds for the radiologic imaging endpoint inclusion criteria: i) has a MAGNIFI-CD score of <7 (range 0-6) on screening pelvic MRI; ii) has a fibrosis-to-fluid ratio of 80% or more (range 80-100%) on screening pelvic MRI
研究组 & 干预措施
Single dose DB-3Q 15 mL direct injection
Experimental
干预措施: DB-3Q (Biological)
Single dose Placebo 15 mL direct injection
Placebo Comparator
干预措施: Placebo (Biological)
Single dose DB-3Q 30 mL direct injection
Experimental
干预措施: DB-3Q (Biological)
Single dose Placebo 30 mL direct injection
Placebo Comparator
干预措施: Placebo (Biological)
Single dose DB-3Q 15 ml IV and DB-3Q 30 mL direct injection
Experimental
干预措施: DB-3Q (Biological)
Single dose Placebo 15 ml IV and Placebo 30 mL direct injection
Placebo Comparator
干预措施: Placebo (Biological)
结局指标
主要结局
Combined Remission
时间窗: 24 Weeks
Clinically confirmed 100% closure of all treated external openings, without development of new fistulas or abscesses and drainage \> 1 cm by the external openings, occurring spontaneously or after gentle finger compression; and on blinded central review of the MRI results, combined imaging endpoint of \>50% reduction in MAGNIFI-CD score and \>20% increase in perianal fistula fibrosis-to-fluid ratio.
次要结局
- Combined Remission(12 Weeks)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
2 期
Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and OlderSARS-CoV-2NCT04405076ModernaTX, Inc.660
已完成
2 期
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus AreasZika VirusNCT04917861ModernaTX, Inc.808
进行中（未招募）
2 期
Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and ToddlersRotavirus GastroenteritisRotavirus InfectionsNCT05621655MAXVAX Biotechnology Limited Liability Company1,512
进行中（未招募）
2 期
Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)Alzheimer DiseaseNCT06427668Spinogenix24
撤回
2 期
Study of MB07811 in Subjects With HypercholesterolemiaHypercholesterolemiaNCT00879112Ligand Pharmaceuticals80